Volume 20, Number 1Bladder Cancer AcademyBladder Cancer Academy 2018 Selected SummariesNermarie Velázquez[Rev Urol. 2018;20(1):31–37 doi: 10.3909/riu02001BCA] © 2018 MedReviews®, LLCImmunotherapyUrinary biomarkersTransurethral resection of a bladder tumorintravesical chemotherapytriomodal therapyrenal masses
Volume 21, Number 1Review ArticlesImmunotherapy in Urological TumorsTreatment ReviewNikhil VasdevAnand SharmaNarin SuleymanOliver JonesThe past decade has seen significant improvement in our understanding of tumor biological features, which has led to use of anti-programmed-death 1 (PD-1) and anti-PD ligand-1 (PD-L1) agents and cytotoxic T lymphocytes antigen 4 (CTLA-4) inhibitors in a multitude of cancers. These immunotherapeutic agents have shown activity in melanoma, lung, head and neck, colorectal, urological, and other cancers. This article details the use of immunotherapy agents in urothelial, renal, prostate, and testicular tumors. [Rev Urol. 2019;21(1):15–20] © 2019 MedReviews®, LLCImmunotherapyCytokinesurological tumorsimmune checkpoint inhibitorsrecombinant BCGcell wall-derived therapies
Volume 21, Number 4Meeting ReviewsProstate Cancer Academy 2019 Selected SummariesJacob Taylor[Rev Urol. 2019;21(4):166–171] © 2020 MedReviews®, LLCProstate cancerImmunotherapyActive surveillanceFocal therapympMRIPSMA-PET
Volume 21, Number 4Review ArticlesIntravesical Therapy for Non-muscle Invasive Bladder Cancer—Current and Future Options in the Age of Bacillus Calmette-Guerin ShortageTreatment UpdateIzak FaienaKarim ChamieVishnukamal GollaAndrew T LenisNon-muscle invasive bladder cancer (NMIBC) is a common and burdensome malignancy. A substantial proportion of patients with intermediate- and high-risk disease will progress to invasive bladder cancer and are at a significant risk for metastasis and death. Bacillus Calmette-Guerin (BCG) therapy for selected cases has been the standard of care for nearly 40 years. Unfortunately, a world-wide shortage has made BCG challenging to obtain. Furthermore, recurrences and progressions do occur. With the US Food and Drug Administration creating a clear path to drug approval for novel treatments, many therapies have been tested, including intravesical cytotoxic chemotherapy, intravesical immunotherapy, systemic immunotherapy, and novel agents, such as gene therapy and targeted therapy. In this review, we highlight ongoing clinical trials. [Rev Urol. 2019;21(4):145–153] © 2020 MedReviews®, LLCImmunotherapyNon-muscle invasive bladder cancerBladder cancerIntravesical treatmentBCG shortage
Volume 22, Number 3Case ReviewFrom Radical to Partial Nephrectomy in the Setting of Solitary Functioning Kidney: Neoadjuvant Treatment of Renal Cell CarcinomaDavid D WatsonNicole G FarhaK James KallailShaker DakhilA J FarhaImmunotherapy has revolutionized the treatment of metastatic renal cell carcinoma (RCC). This case evaluates the use of neoadjuvant immunotherapy for localized RCC in a patient with solitary functioning kidney. A retrospective chart review was conducted between September 2019 and January 2020 on a single patient. Before treatment, the tumor was 7 cm × 8 cm × 8.5 cm. The patient trialed nivolumab + ipilimumab then cabozantinib. The tumor shrunk to 6.3 cm × 5.5 cm and was removed via partial nephrectomy. This case demonstrates the efficacy of immunotherapy in neoadjuvant treatment of RCC. Expansion of guidelines could allow for patients with RCC to undergo partial nephrectomy. [Rev Urol. 2020;22(3):126-129] © 2020 MedReviews®, LLCRenal cell carcinomaImmunotherapyNeoadjuvant immunotherapySolitary kidney